|
End-of-day quote
Korea S.E.
06/10/2026
|
5-day change | 1st Jan Change | ||
| 4,125.00 KRW | +0.12% |
|
+2.36% | -36.54% |
Company Valuation: Cellromax Science Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 |
|---|---|---|
| Market Cap 1 | 57,231 | 73,574 |
| Change | - | 28.56% |
| Enterprise Value (EV) 1 | 35,997 | 66,349 |
| Change | - | 84.32% |
| P/E | 13.4x | 24.9x |
| PBR | 1.25x | 1.55x |
| PEG | - | -0.9x |
| Capitalization / Revenue | 2.65x | 3.32x |
| EV / Revenue | 1.66x | 2.99x |
| EV / EBITDA | 6.06x | 20x |
| EV / EBIT | 6.54x | 23.4x |
| EV / FCF | - | - |
| FCF Yield | - | - |
| Dividend per Share 2 | - | - |
| Rate of return | - | - |
| EPS 2 | 367 | 261 |
| Distribution rate | - | - |
| Net sales 1 | 21,630 | 22,184 |
| EBITDA 1 | 5,936 | 3,314 |
| EBIT 1 | 5,501 | 2,835 |
| Net income 1 | 3,817 | 2,966 |
| Net Debt 1 | -21,234 | -7,226 |
| Reference price 2 | 4,915.00 | 6,500.00 |
| Nbr of stocks (in thousands) | 11,644 | 11,319 |
| Announcement Date | 23/03/26 | 23/03/26 |
1KRW in Million2KRW
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 34M | |
| 7.44x | 1.17x | 6.49x | 3.6% | 33.14B | |
| 16.31x | 4.2x | 9.58x | 1.64% | 25.34B | |
| 18.84x | 1.73x | 11.56x | -.--% | 23.32B | |
| 17.37x | 1.19x | 10.03x | 2.97% | 16.94B | |
| 21.91x | 1.96x | 10x | -.--% | 15.78B | |
| 11.08x | 0.56x | 5.83x | 3.78% | 11.67B | |
| 16.41x | 2.11x | 10.21x | 2.42% | 11.45B | |
| 22.88x | 5.73x | 14.17x | 1.35% | 9.28B | |
| 23.14x | 0.49x | 7.35x | -.--% | 7.32B | |
| Average | 17.26x | 2.13x | 9.47x | 1.75% | 15.43B | |
| Weighted average by Cap. | 15.81x | 2.10x | 9.24x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- A471820 Stock
- Valuation Cellromax Science Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
